CN Patent
CN103772395B — 一类具有parp抑制活性的化合物、其制备方法及用途
Assigned to SHANDONG YIKANG PHARMACEUTICAL CO Ltd · Expires 2016-05-11 · 10y expired
What this patent protects
本发明涉及药物化学和药物治疗学领域,具体涉及一类具有PARP抑制活性的三环吲哚类化合物(I)、其制备方法及用途,其中R 1 、R 1 的定义同说明书。药效学试验证明,本发明的三环吲哚类化合物具有PARP抑制作用,可用于辅助治疗肿瘤疾病。? 。
USPTO Abstract
本发明涉及药物化学和药物治疗学领域,具体涉及一类具有PARP抑制活性的三环吲哚类化合物(I)、其制备方法及用途,其中R 1 、R 1 的定义同说明书。药效学试验证明,本发明的三环吲哚类化合物具有PARP抑制作用,可用于辅助治疗肿瘤疾病。? 。
Drugs covered by this patent
- Talzenna (Talazoparib Tosylate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.